Friday, May 24, 2013
Submit a News Story
Slow-Release "Jelly" Novel Drug Deliverer
Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Biomedical engineers have developed a novel method to overcome the major hurdles facing a promising new class of peptide drugs to treat diseases such as diabetes and cancer.
Full access to this article is for registered users only.
is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Promedior Presents Encouraging Results from Clinical Study of PRM-151
ATS oral presentation of phase 1b data highlights potential for novel mechanism to treat fibrosis.
Patient Openness to Research Can Depend on Race and Sex of Study Personnel
Researchers have found that the race and sex of study personnel can influence a patient’s decision on whether or not to participate in clinical research.
Results of the ROTAVAC Rotavirus Vaccine Study in India
Statement of Anthony S. Fauci, M.D. Director, National Institute of Allergy and Infectious Diseases National Institutes of Health.
Vince and Associates Clinical Research Joins the Altasciences Group
The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
Cocaine Vaccine Passes Key Testing Hurdle
New anti-cocaine vaccine research shows drug can't reach the brain, human clinical trials on the horizon.
Redx Pharma Opens £10.5 Million R&D Centre in UK
Liverpool-based drug discovery and development company Redx Pharma is to open a new research and development facility at AZ's Alderley Park site in Cheshire.
NIH Clinical Trial Begins for Treatment of Rare, Fatal Neurological Disorder
Government, industry, academia, and patient groups collaborate on Niemann-Pick Type C research.
NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial
The trial results appeared in the April 1 issue of the Journal of Infectious Diseases.
Galapagos Discovers Novel Candidate Drug to Treat Breast Cancer
GLPG1790 has high efficacy against triple-negative breast cancer.
Advertise On This Site
Terms & Conditions
©2013 Technology Networks
, all rights reserved.